SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is soaring after its CFO confirmed HBM4 shipments began a quarter early, directly addressing prior "inaccurate reporting" and reiterating that 2026 HBM supply is sold out amidst surging AI demand. The community is abuzz with bullish sentiment and short squeeze predictions as analyst price targets climb on the company's critical role in the memory market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as the community anticipates its upcoming earnings, with high expectations for updates on its oral VK2735 program and strong speculation surrounding its potential to advance directly to Phase 3 development. Investors are actively discussing the significant market opportunity in obesity, fueled by the recent regulatory crackdown on compounded GLP-1s, bolstering conviction in VKTX's "best-in-class" pipeline and increasing buyout or partnership speculation amidst Big Pharma's search for late-stage assets.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending upward as a prominent short-seller retracted their allegations of financial misconduct, fueling community discussion about market manipulation and heightened anticipation for the company's strong earnings report.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to a significant sell-off after its Q4 earnings beat was overshadowed by weaker-than-expected Q1 guidance and ongoing concerns about AI competition. The community is sharply divided between those fearing further downside from AI disruption and others viewing it as an oversold opportunity, highlighting the company's internal growth in areas like Vector ads and Unity 6 adoption.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amidst a short report questioning its flight test progress and certification timeline, sparking community debate over the report's credibility versus Archer's strategic partnerships with major companies and and significant institutional investments. Investors are keenly discussing the company's transparency and technical milestones, anticipating upcoming FAA eIPP selections as a potential catalyst.

Berachain

Berachain (BERA) is gaining attention for recent protocol upgrades and its unique Proof-of-Liquidity model, alongside new reward vaults and integrations that are growing its Total Value Locked. The community is actively discussing its potential as a leading L1 DeFi player, though some express caution regarding past price performance and token dynamics.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amidst intense debate, as founder Charles Hoskinson's vision for mainstream blockchain integration clashes with significant community frustration over its sustained price decline; however, a dedicated group maintains strong bullish conviction, anticipating a major rebound and actively accumulating at current levels.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is trending after reporting strong earnings, raising guidance, and announcing a $1 billion share buyback. Despite the positive news, the stock saw a significant decline, sparking community debate over whether AI disruption fears are outweighing solid fundamentals in the broader software sector.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amidst an intensifying debate over its future, as the launch of T-Mobile's AI translation service amplifies existing concerns that artificial intelligence will render language learning apps obsolete, while bulls point to the company's strong user growth, profitability, and expansion into new educational verticals.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is trending strongly amid anticipation for new privacy features like GhostSend and a structured ecosystem participation model rolling out next week. The community is actively discussing its potential as Solana's default privacy layer, projecting significant growth and revenue sharing for holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocks Steady After Strong Jobs Data Dims Rate-Cut Bets  The Close 2/11/2026

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Yardeni Research's Ed...

<ul class="summary-bullets"><li>It is unclear what the company intends to charge for the vials, the report said.</li><li>Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats. &nbsp;</li><li>Novo also has a pill version of its obesity drug called Wegovy pill launched in early January to regain its slipping market share in the obesity segment.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) is reportedly looking to sell its injectable Wegovy in vials in a move that mirrors rival Eli Lilly and Company (LLY).</p><p>Bloomberg<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials?srnd=homepage-americas"> reported </a>on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year, followed by launches in other countries.</p><p>It is unclear what the company intends to charge for the vials, the report said. &nbsp;</p><h2 class="st-heading-2">Wegovy Upgrade</h2><p>Presently, Novo sells Wegovy in injector pens. Unlike Novo, Eli Lilly sells its obesity drug Zepbound in both injector pen and vial formats. The vials were introduced about two years ago to increase supply, improve access, and offer a lower-cost option.</p><p>Injector pens are the standard auto-injector devices, often preferred for ease of use as they do not require manual drawing of medication. Meanwhile, vials require the use of a separate needle and syringe to draw up the medication.</p><p>Novo also has a pill version of its obesity drug called Wegovy pill launched in early January as it pushes to regain its slipping market share in the obesity segment.</p><h2 class="st-heading-2">Novo’s Disappointing Outlook</h2><p>Novo now <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-shares-tumble-on-q4-miss-weak-sales-forecast/cZbi6tLR4m0">expects</a> adjusted sales to fall between 5% and 13% in fiscal 2026, and operating profit could decline by up to 13%.</p><p>The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S. while issuing the guidance earlier this month.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stock stayed within ‘bearish’ territory over the past 24 hours, while message volume fell from ‘extremely high’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-rallies-as-insiders-buy-company-shares/cZb6pAeR4Ah">ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly 

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

Equity

Novo says it's suing Hims to stop obesity drug copycats

Novo Nordisk Chief Executive Officer Maziar Mike Doustdar says it's suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the...

Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing

Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit...

Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share...

Novo CEO blasts 'mass compounding' of GLP-1 drugs as safety battle escalates

GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.'When you go and try to source raw materials...

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S...

Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?

NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.

Wesbanco Bank Inc. Sells 97,165 Shares of Novo Nordisk A/S $NVO

Wesbanco Bank Inc. trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.9% in the third quarter, according to the company in its most recent filing with the Securities...

Novo Nordisk A/S (NYSE:NVO) Lowered to Strong Sell Rating by Zacks Research

Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Monday...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVONovo Nordisk A/S